Armacokinetic profile. Translation in two sophisticated BC individuals, resulted in no unwanted side effects, confirming prior observations on the biosafety of radiotracers according to the potent GRPR-antagonist [DPhe6 ,LeuNHEt13 ]BBN(6-13) and on GRPR-antagonist radioligands in general. Furthermore, it revealed the capability of [99m Tc]Tc-DB15 to detect various metastatic BC lesions, both in the skeleton and in soft tissues, but these findings ought to be confirmed prospectively in a devoted human study. In view from the above, additional clinical evaluation seems to become warranted to establish the diagnostic worth of [99m Tc]Tc-DB15 in BC, Pc, and other GRPR-expressing human malignancies.Supplementary Supplies: The following are obtainable on-line at https://www.mdpi.com/PKC| article/ ten.3390/cancers13205093/s1, Figure S1: Standard radiochromatogram of HPLC analysis of [99m Tc]TcDB15 (preclinical); Figure S2: Common radiochromatogram of HPLC analysis of [99m Tc]Tc-DB15 (for patients); Figure S3: Entire physique scan 3 h pi of [99m Tc]Tc-DB15 in patient 1 (with anterior and posterior projection); Figure S4: PET/CT 1 h pi of [18 F]FDG in patient 1; Table S1: Numerical biodistribution information for [99m Tc]Tc-DB15 in PC-3 xenograft-bearing SCID mice at 1, four and 24 h pi; Table S2: Numerical biodistribution information for [99m Tc]Tc-DB15 in T-47D xenograft-bearing SCID mice at 1, 4 and 24 h pi.Cancers 2021, 13,12 ofAuthor Contributions: Conceptualization, B.A.N., R.M. and T.M.; methodology, B.A.N., A.K., P.K., B.J., B.B., D.I. and T.M.; validation, B.A.N., R.M., R.C., D.I. and T.M.; investigation, B.A.N., A.K., P.K., B.J., B.B., R.C., D.I. and T.M.; resources, R.M., R.C. and T.M.; information curation, P.K., R.M., R.C. and T.M.; writing–original draft preparation, T.M.; writing–review and editing, all co-authors; supervision, B.A.N., R.M., R.C. and T.M.; project administration, R.M., R.C. and T.M.; funding acquisition, R.M., R.C. and T.M. All authors have read and agreed towards the published version from the manuscript. Funding: The preclinical study was co-financed by Greece as well as the European Union (European Regional Improvement Fund) by means of the project “NCSRD–INRASTES analysis activities inside the framework of your national RIS3” (MIS 5002559), implemented beneath the “Action for the Strategic Development on the Study and Technological Sector”, funded by the Operational System “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020). Additional support was supplied by Siemens AG via the project stablishing a Multidisciplinary and Productive Innovation and Entrepreneurship Hub(E-11928). The preparation of the radioligand for the patient study was supported by the CERAD project, financed beneath Sensible Growth Operational Program 2014020, Priority IV, Measure 4.two. POIR.04.02.004-A001/16. The clinical a part of the study obtained monetary assistance in the Poznan University of Healthcare Sciences (grant No. 502-14-22213550-41147). Institutional Evaluation Board Statement: The animal and patient studies were performed based on the recommendations on the Declaration of Helsinki. The animal protocols have been authorized by the Division of Agriculture and Veterinary Service on the Prefecture of Athens (protocol numbers #1609 for the stability and #1610 for the biodistribution studies, each issued on 11 April 2018). The patient study protocol was authorized by the Bioethical Committee on the Poznan University of Health-related Sciences (selection no. 1153 issued on 16 January 2020). Informed Consent Statement: Individuals gave th.
